Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Diabetes

Free Subscription Articles published in Circulation Retrieve available abstracts of 26 articles: HTML format

Single Articles

September 2025
1. SHI F, Zheng B, Liu Y
   Letter by Shi et al Regarding Article "Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality".
   Circulation. 2025;152:e71-e72.
   PubMed    
   
   
   
2. SILBERNAGEL G, Wen Y, Konrad RJ
   Response by Silbernagel et al to Letters Regarding Article, "Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality".
   Circulation. 2025;152:e73-e74.
   PubMed    
   
   
   
3. HUANG J
   Letter by Huang Regarding Article, "Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality".
   Circulation. 2025;152:e69-e70.
   PubMed    
   
   
   August 2025
4. GAO P, Cao M, Wang X, Zhang H, et al
   G Protein-Coupled Receptor Kinase 3 Exacerbates Diabetic Heart Injuries Through Direct Phosphorylation of Cannabinoid Receptor 2 in Humans and Mice.
   Circulation. 2025 Aug 7. doi: 10.1161/CIRCULATIONAHA.125.073947.
   PubMed     Abstract available
   
   
   May 2025
5. WANG C, Shen S, Kang J, Sugai-Munson A, et al
   METTL3 Is Essential for Exercise Benefits in Diabetic Cardiomyopathy.
   Circulation. 2025 May 13. doi: 10.1161/CIRCULATIONAHA.124.070279.
   PubMed     Abstract available
   
   
   
6. SATTAR N, Weerakkody GJ, McGuire DK, Kosiborod MN, et al
   The Association Between Tirzepatide Versus Insulin Glargine and NT-proBNP Levels in People With Type 2 Diabetes With or at Elevated Risk for Cardiovascular Disease: Post hoc Analyses of SURPASS 4.
   Circulation. 2025;151:1430-1432.
   PubMed    
   
   
   April 2025
7. DONG J, Yang X, Zhang W
   Letter by Dong et al Regarding Article, "Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation".
   Circulation. 2025;151:e962-e963.
   PubMed    
   
   
   
8. BONNESEN K, Heide-Jorgensen U, Schmidt M
   Response by Bonnesen et al to Letter Regarding Article, "Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation".
   Circulation. 2025;151:e964.
   PubMed    
   
   
   March 2025
9. MARX N, Deanfield JE, Mann JFE, Arechavaleta R, et al
   Oral Semaglutide and Cardiovascular Outcomes in Persons With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.
   Circulation. 2025 Mar 29. doi: 10.1161/CIRCULATIONAHA.125.074545.
   PubMed     Abstract available
   
   
   February 2025
10. YU AYX, Auger N, Fu L, Chu A, et al
    Population-Level Screening for Diabetes and Dyslipidemia After Pregnancies Complicated by Hypertension or Diabetes.
    Circulation. 2025;151:508-510.
    PubMed    
    
    
    January 2025
11. 
    Correction to: Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation.
    Circulation. 2025;151:e30.
    PubMed    
    
    
    
12. MORDI IR, McCrimmon RJ, Lang CC
    SGLT Inhibitors in Persons With Heart Failure and Type 1 Diabetes: Filling the Therapeutic Gap.
    Circulation. 2025;151:199-201.
    PubMed    
    
    
    December 2024
13. BIRKENFELD AL, Franks PW, Mohan V
    Precision Medicine in People at Risk for Diabetes and Atherosclerotic Cardiovascular Disease: A Fresh Perspective on Prevention.
    Circulation. 2024;150:1910-1912.
    PubMed    
    
    
    October 2024
14. SILBERNAGEL G, Chen YQ, Li H, Lemen D, et al
    Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality.
    Circulation. 2024 Oct 11. doi: 10.1161/CIRCULATIONAHA.124.069272.
    PubMed     Abstract available
    
    
    August 2024
15. NEUEN BL, Fletcher RA, Heath L, Perkovic A, et al
    Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Circulation. 2024 Aug 30. doi: 10.1161/CIRCULATIONAHA.124.071689.
    PubMed     Abstract available
    
    
    
16. BONNESEN K, Heide-Jorgensen U, Christensen DH, Lash TL, et al
    Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation.
    Circulation. 2024 Aug 29. doi: 10.1161/CIRCULATIONAHA.124.068613.
    PubMed     Abstract available
    
    
    
17. GOPALASINGAM N, Berg-Hansen K, Christensen KH, Ladefoged BT, et al
    Randomized Crossover Trial of 2-Week Ketone Ester Treatment in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.
    Circulation. 2024 Aug 20. doi: 10.1161/CIRCULATIONAHA.124.069732.
    PubMed     Abstract available
    
    
    
18. RAJAGOPALAN S, Dobre M, Dazard JE, Vergara-Martel A, et al
    Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease: The MAGMA Trial.
    Circulation. 2024 Aug 12. doi: 10.1161/CIRCULATIONAHA.123.067620.
    PubMed     Abstract available
    
    
    July 2024
19. NEUEN BL, Claggett BL, Perkovic V, Jardine M, et al
    Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From 4 Large-Scale Placebo-Controlled Outcome Trials.
    Circulation. 2024;150:343-345.
    PubMed    
    
    
    June 2024
20. TANNU M, Kaltenbach L, Pagidipati NJ, McGuire DK, et al
    Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial.
    Circulation. 2024 Jun 27. doi: 10.1161/CIRCULATIONAHA.124.068962.
    PubMed     Abstract available
    
    
    April 2024
21. NEUEN BL, Tuttle KR, Vaduganathan M
    Accelerated Risk-Based Implementation of Guideline-Directed Medical Therapy for Type 2 Diabetes and Chronic Kidney Disease.
    Circulation. 2024;149:1238-1240.
    PubMed    
    
    
    
22. BLOOD AJ, Chang LS, Hassan S, Chasse J, et al
    Randomized Evaluation of a Remote Management Program to Improve Guideline-directed Medical Therapy: The Diabetes Remote Intervention to Improve Use of Evidence-based Medications (DRIVE) Trial.
    Circulation. 2024 Apr 7. doi: 10.1161/CIRCULATIONAHA.124.069494.
    PubMed     Abstract available
    
    
    
23. PATEL SM, Kang YM, Im K, Neuen BL, et al
    Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
    Circulation. 2024 Apr 7. doi: 10.1161/CIRCULATIONAHA.124.069568.
    PubMed     Abstract available
    
    
    March 2024
24. BILLING AM, Kim YC, Gullaksen S, Schrage B, et al
    Metabolic Communication by SGLT2 Inhibition.
    Circulation. 2024;149:860-884.
    PubMed     Abstract available
    
    
    
25. GABA P, Sabik JF, Murphy SA, Bellavia A, et al
    Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main Disease With or Without Diabetes: Findings From a Pooled Analysis of 4 Randomized Clinical Trials.
    Circulation. 2024 Mar 11. doi: 10.1161/CIRCULATIONAHA.123.065571.
    PubMed     Abstract available
    
    
    December 2023
26. OSTERGAARD L, Olesen JB, Petersen JK, Nielsen LS, et al
    Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA(2)DS(2)-VASc 1: A Nationwide Study.
    Circulation. 2023 Dec 28. doi: 10.1161/CIRCULATIONAHA.123.066477.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge.